Abstract | BACKGROUND AND PURPOSE: Breast sarcoma (BS) is a rare tumour. While surgical resection is the primary treatment, the role of radiation therapy (RT) and chemotherapy remains unclear. This study aimed at defining prognostic factors and treatment strategies. MATERIALS AND METHODS: Data from 103 patients treated between 1976 and 2002 were collected. The median age was 55 years (range: 13-86); the median histological tumour size was 4.45 cm (range: 0.8-22). There were 42 angiosarcomas. Surgery consisted of wide excision in 34 cases, and total mastectomy in 69 cases. A total dose of 50 Gy in 25 fractions was delivered in 50 patients. At the completion of treatment, 89 patients had no residual tumour. RESULTS: After a median follow-up of 64 months, 56 patients developed recurrent disease: 38 presented a local relapse and 37 developed distant metastases. The 5-year disease-free survival (DFS) and overall survival (OS) were 44% (95% confidence interval [CI], 39-49%) and 55% (95% CI, 50-60%), respectively. In multivariate analysis, favourable prognostic factors for better local control were: no residual tumour after treatment, no cellular pleomorphism, and histology other than angiosarcoma. For DFS, the five favourable prognostic factors were non-menopausal status, no residual tumour after treatment, non- angiosarcoma histology, absence of tumour necrosis, and grade 1-2 histology. CONCLUSION:
|
Authors | Guilhem Bousquet, Cyril Confavreux, Nicolas Magné, Christine Tunon de Lara, Philip Poortmans, Elzbieta Senkus, Brigitte de Lafontan, Michel Bolla, Remy Largillier, Edouard Lagneau, Sidney Kadish, Claire Lemanski, Mahmut Ozsahin, Yazid Belkacémi |
Journal | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
(Radiother Oncol)
Vol. 85
Issue 3
Pg. 355-61
(Dec 2007)
ISSN: 0167-8140 [Print] Ireland |
PMID | 18023492
(Publication Type: Journal Article, Multicenter Study)
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms
(mortality, therapy)
- Disease-Free Survival
- Female
- Hemangiosarcoma
(mortality, therapy)
- Humans
- Middle Aged
- Prognosis
- Retrospective Studies
- Treatment Outcome
|